ODX.L Regulatory News (ODX)

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Completion of self-test usability study for AbC-19™ Rapid test 

COVID-19 lateral flow antibody test already CE-Marked for professional use

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that the self-test usability study for the UK Rapid Test Consortium's ("UK-RTC") COVID-19 lateral flow antibody test (the "AbC-19™ Rapid test") has concluded.

The study was performed by Ulster University using approximately 2,000 volunteers and completed over the weekend. The AbC-19™ Rapid test has already been CE-Marked for professional use.

Omega remains on track to have production capacity in place this month to produce an initial 100,000 AbC-19™ Rapid test per week, scaling up to 200,000 tests per week capacity in October. If demand through the UK-RTC was to go above 200,000 tests per week, either from the UK Government, or from other third parties, the Company would allocate additional capacity to meet that demand as well.

Colin King, CEO of Omega, commented: "We're very pleased that the self-test usability study has completed and that we are progressing towards our goal of MHRA approval for self-test home use. We cannot give a timescale for when this might be achieved but we look forward to updating shareholders on further developments."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts: 

About the UK-RTC

The UK-RTC was formed in April 2020, when Omega signed a Memorandum of Understanding with Abingdon Health Limited, BBI Solutions Limited, CIGA Healthcare Limited, in conjunction with the University of Oxford, in order to jointly develop and manufacture a COVID-19 Rapid Test as part of the UK Government's five pillar national testing strategy for COVID-19.